Amolyt Pharma

News & Media

Press Releases

Amolyt Pharma to Host Key Opinion Leader Webinar and Discuss Results of Phase I Clinical Trial of AZP-3601 on Friday, October 1st at 10:00am ET

September 10, 2021

Download a PDF copy of this press release: EN Company recently completed a Phase 1 clinical trial in healthy volunteers of AZP-3601 for the potential …

Download a PDF: EN

Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline

September 9, 2021

Download a PDF copy of this press release: EN FR Company to develop AZP-3813 as a potential treatment for acromegaly following successful research collaboration between …

Download a PDF: EN or FR

Amolyt Pharma Announces Appointment of Two Directors

July 8, 2021

Download a PDF copy of this press release: EN FR Elisabeth Svanberg, M.D., Ph.D. brings extensive experience in the development of therapeutics for under-served endocrine, …

Download a PDF: EN or FR

Presentations

  • All PRESENTATIONS
  • AZP-3601
  • AZP-3404
All PRESENTATIONS
  • All PRESENTATIONS
  • AZP-3601
  • AZP-3404
AZP-3601

Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States

Written by
walid
AZP-3601

KOL Webinar on AZP-3601 Featuring John P. Bilezikian, M.D., Ph.D.

Written by
Olivia
AZP-3601

Clinical Burden of Patients with Hypoparathyroidism in the United States: A Claims Data Analysis. ASMBR 2021.

Written by
walid
AZP-3601

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Single and Multiple Administration of AZP-3601, a Novel Long-Acting PTH Analog, to Healthy Adults. ASMBR 2021.

Written by
walid
AZP-3404

Improved Glucose Metabolism and Decreased Weight Gain in Leptin-Resistant, IGFBP2-Deficient, db/db Mice Induced by AZP-3404, a 9-Amino Acid Analog of IGFBP2. e-ECE 2021.

Written by
jpoly4
AZP-3601

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

Written by
jpoly4
AZP-3601

cHP Natural History Study: ISPOR Poster

Written by
jpoly4
AZP-3404

AZP-3404, a Peptide Analog of IGFBP-2, Induces Weight Loss and Improves Glucose Metabolism in Leptin-Resistant db/db Mice. ENDO 2021.

Written by
jpoly4
AZP-3601

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

Written by
jpoly4
AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

Written by
jpoly4
AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Written by
jpoly4

Upcoming events

Date: January 10-13, 2022 (San Francisco, CA.)

Date: February 28, 2022

Date: May 21 - May 24, 2022 (Milan, Italy)

Date: June 1, 2022

Date: June 10 – June 14, 2022 (Atlanta, Georgia)

Date: September 9 - 12, 2022 (Austin, TX)

Social Updates

TWITTER

Scroll to Top